Reviews
1 April 2025
Early Access
https://doi.org/10.4081/reumatismo.2025.1753
The role of leukemia inhibitory factor in autoimmune disorders: insights into recovery and treatment
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
474
Views
126
Downloads
Authors
Objective. Leukemia inhibitory factor (LIF) is a multifunctional cytokine involved in numerous physiological processes, including inflammation and immune response regulation. Recent studies have highlighted its potential role in the pathogenesis and treatment of autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS). This review aims to investigate the role of LIF in various autoimmune disorders and its impact on the recovery and treatment of these diseases.
Methods. A comprehensive literature search was conducted using Google Scholar, PubMed, and Scopus databases. Relevant studies published up to December 2023 were identified using keywords such as “leukemia inhibitory factor”, “autoimmune diseases”, “rheumatoid arthritis” and “multiple sclerosis”.
Results. The literature indicates that LIF has a dual role in autoimmune diseases. In RA, LIF plays an important role in the progression of joint damage by increasing the inflammatory response. In MS, LIF has been shown to promote remyelination and neuroprotection, suggesting its potential as a therapeutic agent. However, the precise mechanisms by which LIF modulates immune responses in these conditions remain incompletely understood.
Conclusions. LIF represents a promising target for treating autoimmune diseases, particularly RA and MS. Further research is required to elucidate its mechanisms of action and develop targeted therapies that can control its beneficial effects while minimizing potential adverse outcomes.
Altmetrics
Downloads
Download data is not yet available.
Citations
Metcalfe S. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun 2011; 12: 157-68. DOI: https://doi.org/10.1038/gene.2011.9
Gough NM, Gearing DP, King JA, Willson TA, Hilton DJ, Nicola NA, et al. Molecular cloning and expression of the human homologue of the murine gene encoding myeloid leukemia-inhibitory factor. Proc Natl Acad Sci U S A 1988; 85: 2623-7. DOI: https://doi.org/10.1073/pnas.85.8.2623
Yue X, Wu L, Hu W. The regulation of leukemia inhibitory factor. Cancer Cell Microenviron 2015; 2: e877.
Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol 2018; 10: a028415. DOI: https://doi.org/10.1101/cshperspect.a028415
Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity 2019; 50: 812-31. DOI: https://doi.org/10.1016/j.immuni.2019.03.027
Zhang C, Liu J, Wang J, Hu W, Feng Z. The emerging role of leukemia inhibitory factor in cancer and therapy. Pharmacol Ther 2021; 221: 107754. DOI: https://doi.org/10.1016/j.pharmthera.2020.107754
Liu YN, Niu S, Chen WY, Zhang Q, Tao Y, Chen WH, et al. Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46ZBTB46-LIF drives CRPC-NE. Clin Cancer Res 2019; 25: 4128-40. DOI: https://doi.org/10.1158/1078-0432.CCR-18-3239
Dahéron L, Opitz SL, Zaehres H, Lensch WM, Andrews PW, Itskovitz‐Eldor J, et al. LIF/STAT3 signaling fails to maintain self‐renewal of human embryonic stem cells. Stem Cells 2004; 22: 770-8. DOI: https://doi.org/10.1634/stemcells.22-5-770
Jiang W, Bai W, Li J, Liu J, Zhao K, Ren L. Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer. Int J Cancer 2021; 148: 1006-13. DOI: https://doi.org/10.1002/ijc.33291
Wang J, Wang K. New insights into Chlamydia pathogenesis: role of leukemia inhibitory factor. Front Cell Infect Microbiol 2022; 12; 1029178. DOI: https://doi.org/10.3389/fcimb.2022.1029178
Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, et al. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun 2019; 10: 3055. DOI: https://doi.org/10.1038/s41467-019-11044-9
Rosario GX, Stewart CL. The multifaceted actions of leukaemia inhibitory factor in mediating uterine receptivity and embryo implantation. Am J Reprod Immunol 2016; 75: 246-55. DOI: https://doi.org/10.1111/aji.12474
Zare F, Saboor-Yaraghi AA, Hadinedoushan H, Dehghan-Manshadi M, Mirzaei F, Mansouri F, et al. Production and characterization of recombinant human leukemia inhibitory factor and evaluation of anti-fertility effects of rabbit anti-rhLIF in Balb/c mice. Protein Expr Purif 2020; 174: 105684. DOI: https://doi.org/10.1016/j.pep.2020.105684
García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). Cancer Invest 2008; 26: 222-9. DOI: https://doi.org/10.1080/07357900701638491
Yavari A, Zare F, Hadinedoushan H, Tahoori MT. The effect of the anti-leukemia inhibitory factor on the immune system in the Balb/c mice bearing breast cancer induced with 4T1 cells. Eur J Med Res 2023; 28: 211. DOI: https://doi.org/10.1186/s40001-023-01196-2
Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C, et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget 2014; 5: 788-801. DOI: https://doi.org/10.18632/oncotarget.1772
Jorgensen MM, de la Puente P. Leukemia inhibitory factor: an important cytokine in pathologies and cancer. Biomolecules 2022; 12: 217. DOI: https://doi.org/10.3390/biom12020217
Liu B, Lu Y, Li J, Liu Y, Liu J, Wang W. Leukemia inhibitory factor promotes tumor growth and metastasis in human osteosarcoma via activating STAT3. APMIS 2015; 123: 837-46. DOI: https://doi.org/10.1111/apm.12427
Gulluoglu S, Sahin M, Tuysuz EC, Yaltirik CK, Kuskucu A, Ozkan F, et al. Leukemia inhibitory factor promotes aggressiveness of chordoma. Oncol Res 2017; 25: 1177-88. DOI: https://doi.org/10.3727/096504017X14874349473815
Lin TA, Wu TS, Li YJ, Yang CN, Illescas Ralda MM, Chang HH. Role and mechanism of LIF in oral squamous cell carcinoma progression. J Clin Med 2020; 9: 295. DOI: https://doi.org/10.3390/jcm9020295
Liu SC, Hsu T, Chang YS, Chung AK, Jiang SS, OuYang CN, et al. Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through modulating YAP1-FAK/PXN signaling. Nat Commun 2018; 9: 5105. DOI: https://doi.org/10.1038/s41467-018-07660-6
Wang D, Liu K, Yang Y, Wang T, Rao Q, Guo W, et al. Prognostic value of leukemia inhibitory factor and its receptor in pancreatic adenocarcinoma. Future Oncol 2020; 16: 4461-73. DOI: https://doi.org/10.2217/fon-2019-0684
Qian L, Xu F, Wang X, Jiang M, Wang J, Song W, et al. LncRNA expression profile of ΔNp63α in cervical squamous cancers and its suppressive effects on LIF expression. Cytokine 2017; 96: 114-22. DOI: https://doi.org/10.1016/j.cyto.2017.04.001
Ciobanu DA, Poenariu IS, Crînguș LI, Vreju FA, Turcu-Stiolica A, Tica AA, et al. JAK/STAT pathway in pathology of rheumatoid arthritis. Exp Ther Med 2020; 20: 3498-503. DOI: https://doi.org/10.3892/etm.2020.8982
Metcalfe SM, Strom TB, Williams A, Fahmy TM. Multiple sclerosis and the LIF/IL-6 axis: use of nanotechnology to harness the tolerogenic and reparative properties of LIF. Nanobiomedicine 2015; 2: 5. DOI: https://doi.org/10.5772/60622
Ansariniya H, Hadinedoushan H, Zare F, Idali F, Shabani M, Mosaffa N. Study the effect of recombinant leukemia inhibitory factor on maintenance of pregnancy and frequency of regulatory T cells in abortion-prone mice. Int Immunopharmacol 2023; 124: 110908. DOI: https://doi.org/10.1016/j.intimp.2023.110908
Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 2016; 12: 25-36. DOI: https://doi.org/10.1038/nrrheum.2015.167
Padyukov L. Genetics of rheumatoid arthritis. Semin Immunopathol 2022; 44: 47-62. DOI: https://doi.org/10.1007/s00281-022-00912-0
Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 296-301. DOI: https://doi.org/10.1097/BOR.0b013e32805e87f1
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42. DOI: https://doi.org/10.1038/nri2094
Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006; 45: 669-75. DOI: https://doi.org/10.1093/rheumatology/kel065
Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 289-95. DOI: https://doi.org/10.1097/BOR.0b013e32805e87ae
Enomoto H, Saito S, Yabe H, Toyama Y, Tomatu T. The levels of leukemia inhibitory factor in synovial tissues of patients with rheumatoid arthritis: inflammation and other proinflammatory cytokines. Mod Rheumatol 2003; 13: 121-8. DOI: https://doi.org/10.3109/s10165-002-0210-9
Chung SJ, Kwon YJ, Park MC, Park YB, Lee SK. The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 2011; 52: 113-20. DOI: https://doi.org/10.3349/ymj.2011.52.1.113
Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1096-105. DOI: https://doi.org/10.1002/art.1780400614
Waring PM, Carroll GJ, Kandiah DA, Buirski G, Metcalf D. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1993; 36: 911-5. DOI: https://doi.org/10.1002/art.1780360707
Nguyen HN, Noss EH, Mizoguchi F, Huppertz C, Wei KS, Watts GFM, et al. Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity 2017; 46: 220-32. DOI: https://doi.org/10.1016/j.immuni.2017.01.004
Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747. DOI: https://doi.org/10.1146/annurev.immunol.23.021704.115707
Rodríguez Murúa S, Farez MF, Quintana FJ. The immune response in multiple sclerosis. Annu Rev i Pathol 2022; 17: 121-39. DOI: https://doi.org/10.1146/annurev-pathol-052920-040318
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015; 15: 545-58. DOI: https://doi.org/10.1038/nri3871
Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol 2019; 26: 27-40. DOI: https://doi.org/10.1111/ene.13819
Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother 2013; 13: 3-9. DOI: https://doi.org/10.1586/14737175.2013.865866
Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108. DOI: https://doi.org/10.1007/s00415-005-0934-5
Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900-13. DOI: https://doi.org/10.1093/brain/awq076
Cao W, Yang Y, Wang Z, Liu A, Fang L, Wu F, et al. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity 2011; 35: 273-84. DOI: https://doi.org/10.1016/j.immuni.2011.06.011
Vanderlocht J, Hellings N, Hendriks JJ, Vandenabeele F, Moreels M, Buntinx M, et al. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis. J Neurosci Res 2006; 83: 763-74. DOI: https://doi.org/10.1002/jnr.20781
Slaets H, Dumont D, Vanderlocht J, Noben JP, Leprince P, Robben J, et al. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 2008; 8: 1237-47. DOI: https://doi.org/10.1002/pmic.200700641
Leibinger M, Müller A, Andreadaki A, Hauk TG, Kirsch M, Fischer D. Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. J Neurosci 2009; 29: 14334-41. DOI: https://doi.org/10.1523/JNEUROSCI.2770-09.2009
Slaets H, Hendriks JJ, Stinissen P, Kilpatrick TJ, Hellings N. Therapeutic potential of LIF in multiple sclerosis. Trends Mol Med 2010; 16: 493-500. DOI: https://doi.org/10.1016/j.molmed.2010.08.007
Metcalfe SM. Multiple sclerosis: one protein, two healing properties. Nature 2011; 477: 287-8. DOI: https://doi.org/10.1038/477287a
Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003; 422: 688-94. DOI: https://doi.org/10.1038/nature01552
Pluchino S, Zanotti L, Brambilla E, Rovere-Querini P, Capobianco A, Alfaro-Cervello C, et al. Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One 2009; 4: e5959. DOI: https://doi.org/10.1371/journal.pone.0005959
Makar TK, Trisler D, Sura KT, Sultana S, Patel N, Bever CT. Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. J Neurol Sci 2008; 270: 70-6. DOI: https://doi.org/10.1016/j.jns.2008.02.011
Kerr BJ, Patterson PH. Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury. Glia 2005; 51: 73-9. DOI: https://doi.org/10.1002/glia.20177
Azari MF, Profyris C, Karnezis T, Bernard CC, Small DH, Cheema SS, et al. Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury. J Neuropathol Exp Neurol 2006; 65: 914-29. DOI: https://doi.org/10.1097/01.jnen.0000235855.77716.25
Emery B, Butzkueven H, Snell C, Binder M, Kilpatrick TJ. Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor. Neuroscience 2006; 137: 463-72. DOI: https://doi.org/10.1016/j.neuroscience.2005.09.022
Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, et al. Astrocytes promote myelination in response to electrical impulses. Neuron 2006; 49: 823-32. DOI: https://doi.org/10.1016/j.neuron.2006.02.006
Janssens K, Van den Haute C, Baekelandt V, Lucas S, van Horssen J, Somers V, et al. Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis. Brain Behav Immun 2015; 45: 180-8. DOI: https://doi.org/10.1016/j.bbi.2014.11.010
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20: 1475. DOI: https://doi.org/10.3390/ijms20061475
Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: From keratinocyte perspective. Cell Death Dis 2022; 13: 81. DOI: https://doi.org/10.1038/s41419-022-04523-3
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci 2019; 20: 4347. DOI: https://doi.org/10.3390/ijms20184347
Nijakowski K, Gruszczyński D, Kolasińska J, Kopała D, Surdacka A. Periodontal disease in patients with psoriasis: a systematic review. Int J Environ Res Public Health 2022; 19: 11302. DOI: https://doi.org/10.3390/ijerph191811302
Szepietowski J, Walker C, Hunter JA, McKenzie RC. Elevated leukaemia inhibitory factor (LIF) expression in lesional psoriatic skin: correlation with interleukin (IL)-8 expression. J Dermatol 2001; 28: 115-22. DOI: https://doi.org/10.1111/j.1346-8138.2001.tb00104.x
Bonifati C, Mussi A, D’Auria L, Carducci M, Trento E, Cordiali-Fei P, et al. Spontaneous release of leukemia inhibitory factor and oncostatin-M is increased in supernatants of short-term organ cultures from lesional psoriatic skin. Arch Dermatol Res 1998; 290: 9-13. DOI: https://doi.org/10.1007/s004030050269
Song K, Wu D. Shared decision-making in the management of patients with inflammatory bowel disease. World J Gastroenterol 2022; 28: 3092-100. DOI: https://doi.org/10.3748/wjg.v28.i26.3092
Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: east meets west. J Gastroenterol Hepatol 2020; 35: 380-9. DOI: https://doi.org/10.1111/jgh.14872
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769-78. DOI: https://doi.org/10.1016/S0140-6736(17)32448-0
Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med 2020; 383: 2652-64. DOI: https://doi.org/10.1056/NEJMra2002697
Guimbaud R, Abitbol V, Bertrand V, Quartier G, Chauvelot-Moachon L, Giroud J, et al. Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course. Eur Cytokine Netw 1998; 9: 607-12.
Zhang YS, Xin DE, Wang Z, Song X, Sun Y, Zou QC, et al. STAT4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation. EMBO J 2019; 38: e99595. DOI: https://doi.org/10.15252/embj.201899595
Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996; 382: 171-4. DOI: https://doi.org/10.1038/382171a0
Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996; 382: 174-7. DOI: https://doi.org/10.1038/382174a0
Kayama H, Takeda K. Regulation of intestinal homeostasis by innate and adaptive immunity. Int Immunol 2012; 24: 673-80. DOI: https://doi.org/10.1093/intimm/dxs094
Goto Y, Ivanov, II. Intestinal epithelial cells as mediators of the commensal-host immune crosstalk. Immunol Cell Biol 2013; 91: 204-14. DOI: https://doi.org/10.1038/icb.2012.80
Zhang S, Jin J, Tian X, Wu L. hsa-miR-29c-3p regulates biological function of colorectal cancer by targeting SPARC. Oncotarget 2017; 8: 104508-24. DOI: https://doi.org/10.18632/oncotarget.22356
Guo J, Zhang R, Zhao Y, Wang J. MiRNA-29c-3p promotes intestinal inflammation via targeting leukemia inhibitory factor in ulcerative colitis. J Inflamm Res 2021; 14: 2031-43. DOI: https://doi.org/10.2147/JIR.S302832
Yamada K, Raska M, Reily C, Anderson JC, Suzuki H, Kiryluk K, et al. Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy. Kidney Dis 2020; 6: 168-80. DOI: https://doi.org/10.1159/000505748
Ichimura Y, Ikei H, Konishi R, Zeniya M, Okai T, Nomura T, et al. Relevance of leukaemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease. Rheumatology 2023; 62: 2267-71. DOI: https://doi.org/10.1093/rheumatology/keac632
Lopez-Dominguez R, Toro-Dominguez D, Martorell-Marugan J, Garcia-Moreno A, Holland CH, Saez-Rodriguez J, et al. Transcription factor activity inference in systemic lupus erythematosus. Life 2021; 11: 299. DOI: https://doi.org/10.3390/life11040299
Viallard JF, Taupin JL, Miossec V, Pellegrin JL, Moreau BL. Analysis of interleukin-6, interleukin-10 and leukemia inhibitory factor (LIF) production by peripheral blood cells from patients with systemic lupus erythematosus identifies LIF as a potential marker of disease activity. Eur Cytokine Netw 1999; 10: 17-24.
How to Cite
The role of leukemia inhibitory factor in autoimmune disorders: insights into recovery and treatment. (2025). Reumatismo. https://doi.org/10.4081/reumatismo.2025.1753
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
